Advance in chimeric antigen receptor T therapy in autoimmune diseases

被引:0
|
作者
Ji, Xiaolan [1 ]
Sun, Yunfan [2 ]
Xie, Yuyang [3 ]
Gao, Jianling [4 ]
Zhang, Ji [1 ]
机构
[1] Suzhou Univ, Affiliated Hosp 2, Dept Ophthalmol, Suzhou, Peoples R China
[2] Nanjing Med Univ, Clin Coll 1, Nanjing, Peoples R China
[3] Suzhou Univ, Suzhou Med Coll, Clin Med Sch 1, Suzhou, Peoples R China
[4] Soochow Univ, Affiliated Hosp 4, Dept Crit Care Med, Suzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
CAR-T; autoimmune diseases; immunotherapy; CAR-Treg; CAAR-T; CELL THERAPY; SUPPRESSION; COLITIS; CANCER;
D O I
10.3389/fimmu.2025.1533254
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autoimmune diseases are a group of diseases in which the body's immune system misrecognizes its own antigens resulting in an abnormal immune response, which can lead to pathological damage to or abnormal functioning of its own tissues. Current treatments are mainly hormones and broad-spectrum immunosuppressants, but these can lead to a decline in the patient's immunity. Chimeric antigen receptor T (CAR-T) Cell therapy has emerged, and now the structure of CAR has changed from first generation to fourth generation of CAR. The significant achievement of CAR-T therapy to B-cell leukemia has also inspired the treatment of autoimmune diseases, and by investigating the mechanisms of different autoimmune diseases, different designs of CAR-T can be used to specifically treat autoimmune diseases. In this review, we will discuss the therapeutic strategies of CAR-T cells in different autoimmune diseases and the limitations of the treatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Chimeric antigen receptor T-cell therapy in hematopoietic and nonhematopoietic malignancies
    Ahmad, Faizan
    BIOMEDICAL AND BIOTECHNOLOGY RESEARCH JOURNAL, 2020, 4 (03): : 179 - 185
  • [22] Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
    Hernandez-Lopez, Alejandrina
    Tellez-Gonzalez, Mario A.
    Mondragon-Teran, Paul
    Meneses-Acosta, Angelica
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [23] Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy
    Feldmann, Anja
    Hoffmann, Anja
    Bergmann, Ralf
    Koristka, Stefanie
    Berndt, Nicole
    Arndt, Claudia
    Rodrigues Loureiro, Liliana
    Kittel-Boselli, Enrico
    Mitwasi, Nicola
    Kegler, Alexandra
    Lamprecht, Chris
    Gonzalez Soto, Karla Elizabeth
    Bachmann, Michael
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [24] Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
    Koedam, Jan
    Wermke, Martin
    Ehninger, Armin
    Cartellieri, Marc
    Ehninger, Gerhard
    CURRENT OPINION IN HEMATOLOGY, 2022, 29 (02) : 74 - 83
  • [25] Chimeric antigen receptor T-cell therapy for melanoma
    Razavi, Azadehsadat
    Keshavarz-Fathi, Mahsa
    Pawelek, John
    Rezaei, Nima
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (03) : 209 - 223
  • [26] Future directions in chimeric antigen receptor T cell therapy
    Maude, Shannon L.
    CURRENT OPINION IN PEDIATRICS, 2017, 29 (01) : 27 - 33
  • [27] Chimeric antigen receptor T cell therapy for multiple myeloma
    Kana Hasegawa
    Naoki Hosen
    Inflammation and Regeneration, 39
  • [28] Chimeric antigen receptor T cell therapy for multiple myeloma
    Hasegawa, Kana
    Hosen, Naoki
    INFLAMMATION AND REGENERATION, 2019, 39 (1)
  • [29] Chimeric antigen receptor T-cell therapy toxicities
    Greenbaum, Uri
    Kebriaei, Partow
    Srour, Samer A.
    Olson, Amanda
    Bashir, Qaiser
    Neelapu, Sattva S.
    Rezvani, Katayoun
    Shpall, Elizabeth J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) : 2414 - 2424
  • [30] CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY FOR ASPERGILLOSIS
    Kumar, P.
    Wurster, S.
    daSilva, T.
    Hauser, P.
    Neelapu, S. S.
    Kontoyiannis, D.
    CYTOTHERAPY, 2024, 26 (06) : S10 - S11